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signiﬁcant improvements in glycemic control (HbA1c 0.59%)
and body weight (BMI 0.52 kg.m-2). The aim of this analysis
was to estimate the long-term clinical and cost implications asso-
ciated with therapy conversion from insulin glargine to detemir
in type 2 diabetes patients in Germany. METHODS: A previ-
ously published and validated diabetes model (CORE Diabetes
Model) was used to make long-term projections of clinical and
cost outcomes based on patient characteristics (age 62.3 years,
duration of diabetes 7 years, HbA1c 8.30%, 50.4% male) and
treatment effects from the German part of PREDICTIVE. The
model was used to estimate life-expectancy, quality-adjusted life
expectancy and to account direct medical costs (pharmacy,
patient management and complication costs). Costs were derived
from published sources and expressed in 2006 Euros. Future
costs and clinical beneﬁts were discounted at 5% annually.
RESULTS: Therapy conversion from insulin glargine to insulin
detemir was projected to improve life expectancy by approxi-
mately 0.13 years (7.08  0.13 versus 6.95  0.12 years) and
quality-adjusted life expectancy by 0.29 quality-adjusted life
years (QALYs) (4.53  0.09 versus 4.24  0.08 QALYs). Direct
costs associated with insulin detemir treatment were projected
to be lower over patient lifetimes than with glargine (€
54,807  1,788 versus € 55,839  1,749 per patient, difference
€ 1,032). Cost savings were driven by lower complication costs
(due to HbA1c improvements) associated with insulin detemir.
CONCLUSION: Modeling the long-term implications of therapy
conversion from insulin glargine to detemir based on data from
German patients in PREDICTIVE indicates that insulin detemir
is associated with beneﬁts in terms of life expectancy, quality-
adjusted life expectancy and complication rates, as well as reduc-
ing costs from a third-party health care payer perspective in
Germany.
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OBJECTIVES: To assess the costs and effects of Januvia versus
Avandia as supplementary treatment in combination with met-
formin, for patients with type 2 diabetes in whom metformin (in
addition to diet and exercise) does not provide adequate glycemic
control. METHODS: The Disease Elimination Life Table Analy-
sis (DELTA) cohort model was used to assess the costs and effects
of Januvia (100 mg) in comparison to Avandia (8 mg). The
model contains ﬁve sub models representing diabetes related
complications. Estimates of disease progression, incidence in the
sub models, disease related mortality, and all cause mortality,
were derived from the UK Prospective Diabetes Study. Estimates
regarding drug efﬁcacy and adverse events were based on an
18-week head-to-head comparison of Januvia 100 mg versus
Avandia 8 mg supplementary to metformin. The analysis was
conducted from a societal perspective. Direct and indirect costs
were included. Effects were reported as (disease-free) life years
and quality-adjusted life years (QALY). To determine the robust-
ness of the model and the impact of uncertainty, uni- and mul-
tivariate sensitivity analyses were carried out. RESULTS: Januvia
is estimated to be the dominant treatment when compared to
Avandia 8 mg. The univariate sensitivity analyses revealed this
conclusion to be robust over a wide range of values. Results from
the multivariate sensitivity analysis estimate the probability that
Januvia combines additional effectiveness with cost savings at
59%, the probability that Januvia gains QALYs at additional
costs at 13%. The probability that Januvia is less effective is
estimated at 28% (15% with cost savings and in 13% with
additional costs). CONCLUSION: Conditional on the correct-
ness of the estimates and assumptions made, Januvia 100 mg is
dominant over 8 mg Avandia. Sensitivity analyses suggest results
are robust to reasonable changes in input parameters.
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OBJECTIVES: The aim of this analysis was to project the long-
term clinical and economic outcomes associated with therapy
conversion to insulin detemir from Neutral Protamine Hagedorn
(NPH) insulin in patients with type 2 diabetes in the German
setting. METHODS: A previously published and validated com-
puter simulation model of diabetes was used to make long-term
projections of clinical and cost outcomes based on patient char-
acteristics and treatment effects from a sub-analysis of the PRE-
DICTIVE study. Data from PREDICTIVE indicated that therapy
conversion from NPH insulin to insulin detemir was associated
with signiﬁcant improvements in glycemic control (HbA1c
-0.6%) and reduced weight gain (body mass index -0.382 kg/
m2). Based on these clinical ﬁndings, the computer simulation
model was used to estimate life-expectancy, quality-adjusted life
expectancy and costs from a third party healthcare payer per-
spective. Future costs and clinical beneﬁts were discounted at 5%
per annum. RESULTS: Conversion to insulin detemir was pro-
jected to improve life expectancy by approximately 0.13 years
compared to NPH (7.08  0.13 versus 6.95  0.12 years) and
quality-adjusted life expectancy by 0.28 quality-adjusted life
years (QALYs) (4.51  0.09 versus 4.23  0.08 QALYs). Direct
medical costs over patient lifetimes were projected to be margin-
ally lower in patients receiving insulin detemir compared to NPH
(€ 54,575  1,842 versus € 54,640  1,739, difference € 65 per
patient). Pharmacy costs were higher with insulin detemir
(€ 14,129 versus € 12,230, difference € 1,899) but were more
than offset by cost savings due to complications avoided (com-
plication costs € 38,246 versus € 40,242, difference € 1,996).
CONCLUSIONS: This modeling study, based on a German sub-
analysis of PREDICTIVE, suggests that therapy conversion from
NPH to insulin detemir is likely to be associated with long-term
clinical beneﬁts and may well be cost saving in type 2 diabetes
patients in the German setting.
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OBJECTIVES: Based on the clinical results of the LAPTOP trial,
a cost analysis from the perspective of the German Statutory
Health Insurance (SHI) was performed. In addition a model
simulation of the long term complications was conducted using
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